Skip to main content
SpringerLink
Log in

The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics and pharmacodynamics of fosinoprilat, the diacid of fosinopril sodium (a new angiotensin-converting enzyme (ACE) inhibitor), were investigated in six haemodialysis patients. Intravenous 14C-fosinoprilat (7.5 mg), oral 14C-fosinopril sodium (10 mg) and oral fosinopril sodium (10 mg) were administered in an open-label, randomized study.

Mean maximum concentration (Cmax), clearance (CL), volume of distribution at steady-state (Vss), mean residence time (MRTiv), and t1/2 values after IV administration of 14C-fosinoprilat were 2,042 μg·ml−1, 11.3 ml·min−1, 11.01, 16.3 h and 28.3 h, respectively. Following oral administration of 14C-fosinopril, mean Cmax, time to maximum plasma concentration (tmax), and fosinoprilat bioavailability values were 197 ng·ml−1, 5.2 h and 29.2 %. Para-hydroxy fosinoprilat and fosinoprilat glucuronide comprised approximately 15 % and 2 % of radioactivity recovered in faeces. Four hours of haemodialysis only cleared approximately 1.5 % of the administered dose. The maximum effect (Emax) model was fitted to the percentage inhibition of serum ACE activity vs. fosinoprilat concentration data in three patients. Emax ranged from 95.3 to 102.5 %, and IC50 (the fosinoprilat concentration required to produce 50 % of Emax) ranged from 2.6 to 4.2 ng·ml−1.

Pharmacokinetic variables of the patients were similar to those in patients with moderate to severe renal dysfunction. Dosage modifications or supplemental dosing following dialysis are unnecessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Duchin KL, Herman TS, O'Leary K, Tu J, Nichola P (1987) Steady-state(SS) kinetics of fosinopril in hypertensive patients (abstract). Clin Pharmacol Ther 41: 227

    Google Scholar 

  2. Bochicchio T, Sandoval G, Ron O, Pérez-Grovas H, Bordes J, Herrera-Acosta J (1990) Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 38: 873–879

    Google Scholar 

  3. Forslund T, Franzén P, Backman R (1990) Comparison of fosinopril and hydrochlorothiazide in patients with mild hypertension (abstract). Am J Hypertens 3: 123A

  4. Sullivan PA, Dineen M, Cervenka J, O'Connor DT (1988) Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension. Am J Hypertension 1: 280S-283S

    Google Scholar 

  5. Anderson RJ, Duchin KL, Gore RD, et al (1991) Once-daily fosinopril in the treatment of hypertension. Hypertension 17: 636–642

    Google Scholar 

  6. Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M (1988) Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 25: 9–15

    Google Scholar 

  7. Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N (1991) Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 457–467

    Google Scholar 

  8. Gehr TWB, Sica DA, Grasela DM, Fakhry I, Davis J, Duchin KL (1991) Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 41: 165–169

    Google Scholar 

  9. Gehr TWB, Sica DA, Brater DC, Davis J, Fakhry I (1988) Furosemide pharmacokinetics and pharmacodynamics in renal transplantation. Clin Pharmacol Ther 43: 547–553

    Google Scholar 

  10. Swanson BN, Stauber KL, Alpaugh WC, Weinstein SH (1985) Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine. Anal Biochem 148: 401–407

    Google Scholar 

  11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York, pp 409–417

    Google Scholar 

  12. Donnelly R, Meredith PA, Elliott HL, Reid JL (1990) Kineticdynamic relations and individual responses to enalapril. Hypertension 15: 301–309

    Google Scholar 

  13. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ (1984) Elimination kinetics of captopril in patients with renal failure. Kidney Int 25: 942–947

    Google Scholar 

  14. Lowenthal DT, Irvin JD, Merrill D, et al (1985) The effect of renal function on enalapril kinetics. Clin Pharmacol Ther 38: 661–666

    Google Scholar 

  15. Kelly JG, Doyle GD, Carmody M, Glover DR, Cooper WD (1988) Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Br J Clin Pharmacol 26: 781–786

    Google Scholar 

  16. Fruncillo RJ, Rocci ML, Vlasses PH, et al (1987) Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int 31 [Suppl 20]: S117-S122

    Google Scholar 

  17. Jackson B, Cubela RB, Conway EL, Johnston CI (1988) Lisinopril pharmacokinetics in chronic renal failure. Br J Clin Pharmacol 25: 719–724

    Google Scholar 

  18. van Schaik BAM, Geyskes GG, Boer P (1987) Lisinopril in hypertensive patients with and without renal failure. Eur J Clin Pharmacol 32: 11–16

    Google Scholar 

  19. Debusmann ER, Pujadas JO, Jahn W, et al (1987) Influence of renal function on the pharmacokinetics of rampiril (HOE 498). Am J Cardiol 59;70D-78D

    Google Scholar 

  20. Shionoiri H, Miyakawa T, Yasuda G, et al (1987) Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension. J Cardiovasc Pharmacol 10 [Suppl 7]: S145-S147

    Google Scholar 

  21. Schunkert H, Kindler J, Gassmann M, et al (1989) Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. Eur J Clin Pharmacol 37: 249–256

    Google Scholar 

  22. Shionoiri H, Gotoh E, Sugimoto K, Takasaki I, Minamisawa K, Ishii M (1989) Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function. Br J Clin Pharmacol 27: 283 S-287 S

    Google Scholar 

  23. Fillastre JP, Moulin B, Godin M, et al (1989) Pharmacokinetics of cilazapril in patients with renal failure. Br J Clin Pharmacol 27: 275 S-282 S

    Google Scholar 

  24. Onoyama K, Hirakata H, Iseki K, et al (1981) Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension 3: 456–459

    Google Scholar 

  25. Kaiser G, Ackermann R, Sioufi A (1989) Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am Heart J 117: 746–751

    Google Scholar 

  26. Rakhit A, Radensky P, Szerlip HM, et al (1988) Effect of renal impairment on disposition of pentopril and its active metabolite. Clin Pharmacol Ther 44: 39–48

    Google Scholar 

  27. Biollaz J, Schelling JL, Jacot Des Combes B, et al (1982) Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol 14: 363–368

    Google Scholar 

  28. Vlasses PH, Larijani GE, Conner DP, Ferguson RK (1985) Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. Clin Pharm 4: 27–40

    Google Scholar 

  29. Ferguson RK, Vlasses PH, Swanson BN, et al (1982) Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Ther 32: 48–53

    Google Scholar 

  30. DeForrest JM, Waldron TL, Harvey C, et al (1989) Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology. J Cardiovasc Pharmacol 14: 730–736

    Google Scholar 

  31. Unger T, Ganten D, Lang RE, Schölkens BA (1985) Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 7: 36–41

    Google Scholar 

  32. Krause JZ, Matarese RA, Zabetakis PM, Michelis MF (1980) Reversibility of hyporeninemia and hypoaldosteronemia in chronic haemodialysis patients by correction of fluid excess. J Lab Clin Med 96: 734–742

    Google Scholar 

  33. Krämer BK, Ress KM, Ulshöfer TM, Risler T (1987) The reninangiotensin-aldosterone system during haemodialysis with acetate or bicarbonate at different dialysate sodium concentrations. Nephrol Dial Transplant 2: 531–536

    Google Scholar 

  34. Weidmann P, Maxwell MH (1975) The renin-angiotensin-aldosterone system in terminal renal failure. Kidney Int [Suppl]: S219–S234

  35. Wauters J-P, Waeber B, Brunner HR, Guignard J-P, Turini GA, Gavras H (1981) Uncontrollable hypertension in patients on haemodialysis: Long-term treatment with captopril and salt restriction. Clin Nephrol 16: 86–92

    Google Scholar 

  36. Iseki K, Onoyama K, Fujimi S, Omae T (1981) Immediate hemodynamic response to SQ 14225(captopril) in hypertensive and normotensive haemodialysis patients. Clin Nephrol 16: 137–141

    Google Scholar 

  37. Kornerup JH, Schmitz O, Danielsen H, Pedersen EB, Giese J (1984) Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease. Contr Nephrol 41: 123–127

    Google Scholar 

  38. Zuccala A, Santoro A, Ferrari G, Zucchelli P (1988) Pathogenesis of hypertension in haemodialysis patients: A pharmacological study. Kidney Int [Suppl 25]: S190–S191

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Medical College of Virginia, Richmond, Virginia, USA

    T. W. B. Gehr & D. A. Sica

  2. Department of Human Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA

    D. M. Grasela & K. L. Duchin

Authors
  1. T. W. B. Gehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. A. Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. M. Grasela
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. L. Duchin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gehr, T.W.B., Sica, D.A., Grasela, D.M. et al. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. Eur J Clin Pharmacol 45, 431–436 (1993). https://doi.org/10.1007/BF00315514

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315514

Key words

Search

Navigation